A personalized approach to omalizumab therapy in patients with chronic spontaneous urticaria: case series

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic spontaneous urticaria (CSU) is one of the most common skin diseases and leads to a significant decrease in the quality of life of patients. In some cases, in the presence of angioedema of certain localizations, this disease can lead to life-threatening conditions. Patients whose CSU is not controlled by fourfold doses of non-sedating antihistamines require genetically engineered biological therapy (GEBT) with omalizumab. Wherein, it is not always possible to achieve complete control of CSU using standard doses of this drug. Current therapeutic strategies allow achieving a complete response to therapy by escalating doses of omalizumab. This article presents the clinical experience of successful personalized selection of GIBT in patients with severe CSU, refractory to standard treatment.

Full Text

Restricted Access

About the authors

Anna Yu. Petukhova

Central City Clinical Hospital № 6

Author for correspondence.
Email: anna-petuhova@mail.ru
ORCID iD: 0000-0002-5103-2446

Cand. Sci. (Med.), Headof the Outpatient Consultative Department of Allergology and Immunology

Russian Federation, Yekaterinburg

References

  1. Zuberbier T., et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–66.
  2. Gaig P., Olona M., Munoz Lejarazu D., et al. Epidemiology of urticaria in Spain. J. Investig. Allergol. Clin. Immunol. 2004;14:214–20. doi: 10.1111/all.15090.
  3. Toubi E., Kessel A., Avshovich N., et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59:869–73. doi: 10.1111/j.1398-9995.2004.00473.x.
  4. van der Valk P.G., Moret G., Kiemeney L.A. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146:110–13. doi: 10.1046/j.1365-2133.2002.04582.x.
  5. Maurer M., Weller K., Bindslev-Jensen C., et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66:317–30. doi: 10.1111/j.1398-9995.2010.02496.x.
  6. O’Donnell B.F., Lawlor F., Simpson J., et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197–201.
  7. Baiardini I., Giardini A., Pasquali M., et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003;58:621–23. doi: 10.1034/j.1398-9995.2003.00091.x.
  8. Schoepke N., Asero R., Ellrich A., et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study. Allergy. 2019;74(12):2427–36. doi: 10.1111/all.13949.
  9. Kolkhir P., Church M.K., Weller K., et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772–81. doi: 10.1016/j.jaci.2016.08.050.
  10. Maurer M., Eyerich K., Eyerich S., et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020;181(5):321–33. doi: 10.1159/000507218.
  11. Altrichter S., Zampeli V., Ellrich A., et al. IgM and IgA in addition to IgG autoantibodies against FcεRIα are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy. 2020;75:3208–15. doi: 10.1111/all.14412.
  12. Metz M., Krull C., Hawro T., et al. Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. J Invest Dermatol. 2014;134(11):2833–36. doi: 10.1038/jid.2014.226.
  13. Kolkhir P., Church M.K., Altrichter S., et al. Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity and poor response to treatment. J Allergy Clin Immunol Pract. 2020;8:318–25. doi: 10.1016/j.jaip.2019.08.025.
  14. Maurer M., Raap U., Staubach P., et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy. 2019;49:655–62. doi: 10.1111/cea.13309.
  15. Shahar E., Bergman R., Guttman-Yassky E., Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol. 2006;45(10):1224–27. doi: 10.1111/j.1365-4632.2006.02655.x.
  16. Boushey H.A. Experiences withmonoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol. 2001;108(Suppl. 2):S77–83. doi: 10.1067/mai.2001.116434.
  17. Bracken S.J., Abraham S., MacLeod A.S. Autoimmune theories of chronic spontaneous urticaria. Front Immunol. 2019;10:627. doi: 10.3389/fimmu.2019.00627.
  18. Hochhaus G., Brookman L., Fox H., et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19(6):491–98. doi: 10.1185/030079903125002171.
  19. Metz M., Staubach P., Bauer A., et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc epsilon RI-positive cells in the skin. Theranostics. 2017;7(5):1266–76. doi: 10.7150/thno.18304.
  20. Kaplan A., Ledford D., Ashby M., et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–9. doi: 10.1016/j.jaci.2013.05.013.
  21. Maurer M., Rosen K., Hsieh H.J., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–35. doi: 10.1056/NEJMoa1215372.
  22. Saini S.S., Bindslev-Jensen C., Maurer M., et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on h1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75. doi: 10.1038/jid.2014.306.
  23. Labrador-Horrillo M., Valero A., Velasco M., et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in reallife practice. Expert Opin Biol Ther. 2013;13(9):1225–28. doi: 10.1517/14712598.2013.822484.
  24. Metz M., Ohanyan T., Church M.K., Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73(1):57–62. doi: 10.1016/j.jdermsci.2013.08.011.
  25. Rottem M., Segal R., Kivity S., et al. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience. Isr Med Assoc J. 2014;16(8):487–90.
  26. Sussman G., Hebert J., Barron C., et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014;112(2):170–74. doi: 10.1016/j.anai.2013.12.005.
  27. Thomsen S.F., Pritzier E.C., Anderson C.D., et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre aware study. J Eur Acad Dermatol Venereol. 2017;31(6):1048–55. doi: 10.1111/jdv.14210.
  28. Metz M., et al. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clin Rev Allergy Immunol. 2020;59:38–45. doi: 10.1007/s12016-020-08794-6.
  29. Turk M., Kocaturk E., Cure K., Yilmaz I. Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria. J Allergy Clin Immunol Pract. 2018;6:1389–90. doi: 10.1016/j.jaip.2018.01.027.
  30. Kocaturk E., Deza G., Kiziltac K., Gimenez-Arnau A.M. Omalizumab updosing for better disease control in chronic spontaneous urticaria patients. Int Arch Allergy Immunol. 2018;177:360–64. doi: 10.1159/000491530.
  31. Song C.H., Stern S., Giruparajah M., et al. Long-term efficacy of fixed dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2013;110:113–17. doi: 10.1016/j.anai.2012.11.022.
  32. Silva P.M., Costa A.C., Mendes A., Barbosa M.P. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol. (Madr). 2015;43:168–73. doi: 10.1016/j.aller.2013.11.007.
  33. Metz M., Ohanyan T., Church M.K., Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57–62. doi: 10.1016/j.jdermsci.2013.08.011.
  34. Buyukozturk S., Gelincik A., Demirturk M., et al. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol. 2012;39:439–42. doi: 10.1111/j.1346-8138.2011.01473.x.
  35. Kaplan A., Ferrer M., Bernstein J.A., et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474–81. doi: 10.1016/j.jaci.2015.08.023.
  36. Gericke J., Metz M., Ohanyan T., et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139:1059–61. doi: 10.1016/j.jaci.2016.07.047.
  37. Nettis E., Cegolon L., Di Leo E., et al. Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response. Ann Allergy Asthma Immunol. 2018;121:474–78. doi: 10.1016/j.anai.2018.06.014.
  38. Бурыгина Е.В., Козлова Я.И., Климко Н.Н. Хроническая спонтанная крапивница: диагностические и прогностические маркеры. Врач. 2020;31(7):10–7. [Burygina E., Kozlova Y., Klimko N. Chronic spontaneous urticaria: markers for diagnosis and prognosis. Vrach. 2020;31(7):10–7 (In Russ.)]. doi: 10.29296/25877305-2020-07-02.
  39. Ornek S., Kocaturk E. A patient-oriented approach to longterm use of omalizumab in chronic spontaneous urticarial. Cutan Ocular Toxicol. 2021. doi: 10.1080/15569527.2021.1945618.
  40. Metz M., Vadasz Z., Kocaturk E., Gimenez-Arnau A.M. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clin Rev Allergy Immunol. 2020;59(1):38–45. doi: 10.1007/s12016-020-08794-6.
  41. Curto-Barredo L., Spertino J., Figueras-Nart I., et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol. 2018;179:210–12. Doi: /10.1111/bjd.16379.
  42. Salman A., Comert E. The real-life effectiveness and safety of omalizumab updosing in patients with chronic spontaneous urticaria. J Cutan Med Surg. 2019;23(5):496–500. Doi: 10.1177/ 1203475419847956.
  43. Milgrom H., Fowler-Taylor A., Vidaurre C.F., Jayawardene S. Safety and tolerability of omalizumab in children with allergic (igemediated) asthma. Curr Med Res Opin. 2011;27(1):163–69. doi: 10.1185/03007995.2010.539502.
  44. Normansell R., Walker S., Milan S.J., et al. () Omalizumab for asthma in adults and children. Cochrane Database Syst. Rev. 2014;1:Cd003559. doi: 10.1002/14651858.CD003559.pub4.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies